A practical reference on MC4 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
== Introduction == The field of biotextiles has garnered significant attention due to its potential to revolutionize the textile industry by offering sustainable alternatives to conventional and environmentally harmful fabrics. Central to this innovation are raw materials derived from nature's own processes, including mycelium, bacterial cellulose and vegetable and fruit biomass. These natural ingredients have potential to become a reliable source for the development of eco-friendly textiles, addressing issues with environmental degradation and ingredient depletion associated with traditional textile production. Processing of these materials offer abundant sources of natural fibers. Using the fibrous structures found in these materials and plant tissues, such as cotton, hemp, flax and more, its possible to create biodegradable and renewable textiles. Washing, drying and a variety of spinning techniques are common for processing of all textiles but the processing for biotextiles is expected to produce less environmentally harmful waste products due to the bio-remedial nature of many of the natural materials. Furthermore, advancements in processing have enabled the extraction of fibers for fashion from unconventional sources, including pineapple, banana, citrus fruits, animal byproducts and bone. These new developments make large contributions to the world of innovative fashion.
A flexible intermediate bulk container, FIBC, big bag, bulk bag, or super sack is a standardized container in large dimensions for storing and transporting granular products. It is often made of a woven synthetic material.
The R1 plasmid is a plasmid that was first isolated from Salmonella paratyphi bacteria in 1963. It is a short plasmid, composed of 97,566 nucleotides and 120 genes, that belongs to the IncFII plasmid group. There are about one to two copies of the R1 plasmid per chromosome. The R1 plasmid imparts multi-drug antibiotic resistance to its host bacteria. The "R" in "R1" stands for "resistance", and the R1 plasmid contains resistance factors, or R factors, giving it the power to resist certain antibiotics. It's known as a "low copy" plasmid, meaning that it exists in relatively few copies in any given bacteria. This characteristic allows the R1 plasmid to have an efficient plasmid stabilization system, that aids in stabilizing medium copy number plasmids. R1 must rely on a "Type II" segregation system. This plasmid system ensures that at least one copy is contained in each daughter cell after cell division.
Sources: en.wikipedia.org
== Applications == Ammonium sulfate precipitation is a useful technique as an initial step in protein purification because it enables quick, bulk precipitation of cellular proteins. It is also often employed during the later stages of purification to concentrate protein from dilute solution following procedures such as gel filtration. The drawback of this method is that oftentimes different substances can precipitate along with the protein, and other purification techniques must be performed, such as ion chromatography or size-exclusion chromatography.
24395Am + 2210Ne → 265−x105 + x n (x = 4, 5) After observing the alpha decays of element 105, the researchers aimed to observe spontaneous fission (SF) of the element and study the resulting fission fragments. They published a paper in February 1970, reporting multiple examples of two such activities, with half-lives of 14 ms and 2.2±0.5 s. They assigned the former activity to 242mfAm and ascribed the latter activity to an isotope of element 105. They suggested that it was unlikely that this activity could come from a transfer reaction instead of element 105, because the yield ratio for this reaction was significantly lower than that of the 242mfAm-producing transfer reaction, in accordance with theoretical predictions. To establish that this activity was not from a (22Ne,xn) reaction, the researchers bombarded a 243Am target with 18O ions; reactions producing 256103 and 257103 showed very little SF activity (matching the established data), and the reaction producing heavier 258103 and 259103 produced no SF activity at all, in line with theoretical data. The researchers concluded that the activities observed came from SF of element 105. In April 1970, a team at Lawrence Berkeley Laboratory (LBL), in Berkeley, California, United States, claimed to have synthesized element 105 by bombarding californium-249 with nitrogen-15 ions, with an alpha activity of 9.1 MeV. To ensure this activity was not from a different reaction, the team attempted other reactions: bombarding 249Cf with 14N, Pb with 15N, and Hg with 15N. They stated no such activity was found in those reactions.
In August 2025, the United States began a military buildup in the southern Caribbean, deploying warships and military personnel. The Central Intelligence Agency (CIA) sent a team into Venezuela that began tracking Maduro's movements, using a source close to the Venezuelan president, and plans were made for the capture of Maduro months in advance. The Delta Force and other participants in the operation erected a mockup of the safe house in which Maduro was believed to be hiding, described by Trump as a "very highly guarded ... fortress". In September, the United States Southern Command began conducting military strikes on vessels in the Caribbean Sea, alleging some were trafficking drugs on behalf of Venezuela. In November 2025, Venezuelan opposition leader María Corina Machado promised to open Venezuela's oil and gas reserves during a business meeting in Miami attended by Trump, and the Trump administration engaged in secret talks with Maduro's government about its oil reserves. In December 2025, this escalated to include seizures of sanctioned oil tankers carrying Venezuelan crude. These seizures formed part of the broader blockade on sanctioned oil preceding the January 2026 operation. The US also launched covert operations in Venezuela under the directive of the CIA in late December. On 2 January 2026, Trump announced that the US military would conduct strikes inside Venezuela. In the weeks preceding the operation, Trinidad and Tobago signed an agreement with the US to allow US military access to its airports.
==== Magnetic Resonance Imaging (MRI) Detection ==== Over the past two decades, iron oxide nanoparticles for biomedical use had increased dramatically, largely due to its ability of non-invasive imaging, targeting and triggering drug release, or cancer therapy. Stem or immune cell could be marked with iron oxide nanoparticles to be detected by Magnetic resonance imaging (MRI). However, the concentration of iron oxide nanoparticles needs to be high enough to enable the significant detection by MRI. Due to the limited understanding of physicochemical nature of iron oxide nanoparticles in biological systems, more research is needed to ensure nanoparticles can be controlled under certain conditions for medical usage without posing harm to humans.
Sources: en.wikipedia.org
==== Infections ==== Some observational studies have detected significant associations between benzodiazepines and respiratory infections such as pneumonia where others have not. A large meta-analysis of pre-marketing randomized controlled trials on the pharmacologically related Z-Drugs suggest a small increase in infection risk as well. An immunodeficiency effect from the action of benzodiazepines on GABA-A receptors has been postulated from animal studies.
In July 2023, amid escalating tensions in the South China Sea, Chinese President Xi Jinping invited Duterte to Beijing. During the meeting, Xi asked Duterte to "play an important role" in improving Philippine-China relations, which were rapidly deteriorating under the Marcos administration that sought to gravitate towards the United States by expanding the number of bases American troops can access under the EDCA. As the meeting did not involve the Marcos administration, the event gained much attention, and the administration wanted details of the Xi-Duterte discussion. Duterte visited Malacanang Palace later and, in a closed-door session, discussed the matter with Marcos, though no further details were provided to the media.
National Food and Nutrition Policy Brazilian Dietary Guidelines (Guia Alimentar para a População Brasileira) National School Feeding Program Physical activity promotion campaigns Food labelling regulations The Brazilian Dietary Guidelines, first published in 2014, received international recognition for emphasising minimally processed foods and warning against excessive consumption of ultra-processed foods. Public health experts continue to debate additional interventions, including taxation of sugar-sweetened beverages, restrictions on food marketing directed at children, and expanded access to obesity treatment services.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.